Key Takeaway: CG Oncology is set to present late-breaking findings at EAU 2025, showcasing their ongoing commitment to advancing bladder cancer treatment. The company recently reported positive results from the CORE-1008 trial, which evaluates intravesical combination therapy for high-risk patients. Additionally, CG Oncology will participate in various investor conferences in June.
Price reaction · baseline $27.92 (2025-03-21T17:26:00.000Z) · hit during market hours · 5 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-3.1%
Market Sentiment Analysis
POSITIVE FACTORS
CG Oncology is actively participating in multiple upcoming conferences.
Positive results reported from the CORE-1008 trial indicate potential for new treatments.
The company is recognized for its contributions to bladder cancer research.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer
Full Press Release Details
by admin | Mar 21, 2025 | congress-hub-presentations
Recent Posts
• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation
Recent Comments
Frequently Asked Questions
What will CG Oncology present at EAU 2025?
CG Oncology will present late-breaking findings related to their bladder cancer research.
What are the CORE-1008 trial results?
The CORE-1008 trial reported positive results for intravesical combination therapy in high-risk patients.
When is CG Oncology participating in investor conferences?
CG Oncology is scheduled to participate in upcoming investor conferences in June.
What is the focus of CG Oncology's research?
CG Oncology focuses on developing treatments for non-muscle invasive bladder cancer.